The POSH (Prospective Study of Outcomes in Sporadic and Hereditary breast cancer) trial [26] indicated that BRCA1/2 PV carriers with TNBC might experience an early survival advantage compared to noncarriers within the first 2 years after diagnosis; however, this benefit diminished over time, resulting in similar long-term outcomes. This evidence concerns the gene BRCA1 and breast carcinoma.